Short answer
Solid Biosciences Inc. (SLDB) filed its Q3 2025 10-Q quarterly report on Nov 3, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$46M
- −39.9% YoY · −15.9% QoQ
- EPS (diluted)
- −$0.48
- +39.2% YoY · −23.1% QoQ
Source: XBRL data from the Solid Biosciences Inc. (SLDB) Q3 2025 10-Q on SEC EDGAR. USD.
Solid Biosciences Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no commercial product revenue generated
- Net loss $45.8M vs $32.7M YoY, with operating loss $48.1M vs $35.2M
- SGT-003 R&D $18.1M, up 242.8% YoY; SGT-212 R&D $1.8M, down 64.4%
- Cash, equivalents and available-for-sale securities $236.1M at September 30, 2025, funding operations into first half of 2027
- Near-term focus: dose 30 INSPIRE DUCHENNE participants by early 2026 and pursue FDA regulatory-pathway discussions in first half of 2026
Risk Factors
- No material-change comparison provided; risk-factor section reiterates carried-forward risks from the 10-K
- Cash, cash equivalents, and available-for-sale securities expected to fund operations into first half of 2027
- Net loss $124.5 million for nine months ended September 30, 2025, with accumulated deficit of $908.0 million
- INSPIRE DUCHENNE trial includes one treatment-related serious adverse event involving Grade 3 immune-mediated myositis
- Uninsured cash balances above the FDIC’s $250,000 standard deposit insurance limit expose near-term liquidity to bank failures
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Solid Biosciences Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.